Thomas has been active in the biotech and medtech business for >30 years. He is currently the CEO of Altamira Therapeutics Ltd., a biomedical company developing therapeutics for indications in oncology, neurotology, allergology and infectiology. In this role, he designed and oversaw 14 clinical trials, ranging from Phase 1 to Phase 3. Prior to founding Altamira Therapeutics in 2003, he was the CEO of Disetronic Group, a fast-growing Swiss drug delivery company.